Impact on ALL protocol
CSVT has impacted treatment in almost all patients who developed this
complication. This affected patient by delaying or deleting subsequent
doses and thus compromising maximal benefit from treatment. In the
majority of patients with CSVT, there was omission of few ASP doses,
whereas the vast majority had to miss or delay doses of ASP until CSVT
stabilized on anticoagulant therapy. Steroids were as well missed or
delayed because of such complication. ASP was omitted from the whole
treatment in one patient who had a life-threatening superior sagittal
sinus thrombosis that was complicated by a large intracranial hemorrhage
(ICH) and required two craniotomies.